Last reviewed · How we verify

Salvage Therapy

H. Lee Moffitt Cancer Center and Research Institute · FDA-approved active Small molecule

Salvage therapy refers to treatment regimens administered to patients who have failed or become resistant to standard first-line cancer therapies.

Salvage therapy refers to treatment regimens administered to patients who have failed or become resistant to standard first-line cancer therapies. Used for Recurrent or refractory malignancies (specific indication depends on cancer type and prior treatment history).

At a glance

Generic nameSalvage Therapy
Also known asprostatectomy, Sofosbuvir,simeprevir, daclatasvir, ribavirin or sofosbuvir and querevo
SponsorH. Lee Moffitt Cancer Center and Research Institute
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Salvage therapy is not a single drug but rather a clinical approach using alternative chemotherapy agents, targeted therapies, or immunotherapies in patients with recurrent or refractory malignancies. The specific mechanism depends on the individual agents selected and the cancer type being treated. These regimens are designed to overcome resistance mechanisms that emerged during initial treatment.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: